Your Health, We Care
Release date: 2026-01-13 17:47:04 Recommended: 130
As a novel AKT inhibitor, the drug interactions of capivasertib represent a critical aspect that must be prioritized in clinical practice.
Concurrent use of this drug with any of the following medications is generally not recommended, but may be necessary in certain cases. These medications include:
Adenovirus type 4 vaccine (live attenuated), adenovirus type 7 vaccine (live attenuated), amphetamine, amprenavir, apalutamide, aprepitant, atazanavir, avacopan, bedaquiline, benzphetamine, boceprevir, bosentan, brexpiprazole, carbamazepine, cenobamate, ceritinib, cholera vaccine, ciprofloxacin, clarithromycin, clofazimine, clomipramine, cobicistat, codeine, colchicine, conivaptan, crizotinib, cyclosporine, dabrafenib, darunavir, dextroamphetamine, diltiazem, metamizole sodium, doxorubicin, doxorubicin hydrochloride liposome, dronedarone, duvelisib, Zaire ebolavirus vaccine (live attenuated), efavirenz, elagolix and eliglustat.
If these drugs are prescribed concomitantly, your doctor may adjust the dosage or administration frequency of one or both medications.
The presence of other medical conditions may affect the use of this drug. It is crucial to inform your doctor if you have any other medical issues, especially the following conditions which may be exacerbated:
diabetes mellitus, history of hyperglycemia, infections, liver disease, and skin disorders. Caution is required in such cases.
Capivasertib is an anticancer drug indicated for the treatment of breast cancer in adults. It is used for patients with locally advanced (spread to adjacent areas) or metastatic (spread to other parts of the body) breast cancer that has relapsed or progressed following hormonal therapy.
This drug is indicated for cancers that express specific hormone receptors on the surface of cancer cells (i.e., estrogen receptor-positive) and do not overexpress another receptor known as HER2 (i.e., HER2-negative). Additionally, the presence of one or more mutations in the PIK3CA, AKT1, or PTEN genes in cancer cells must be confirmed by testing.
Capivasertib should be administered in combination with fulvestrant, an anti-estrogen drug.
For premenopausal or perimenopausal women receiving capivasertib, concurrent administration with a gonadotropin-releasing hormone (GnRH) agonist (a drug that reduces estrogen and progesterone levels in the blood) is also required.
